ALERTS & COVID-19 UPDATES Learn more: COVID-19 Resources; COVID-19 Testing; Vaccine Info; Visitor Policy; Support Us

[LCID Study Number: 2017-004]

A Multicenter, Double-Blind, Randomized, Comparative Study of the Safety, Tolerability, Efficacy, and Pharmacokinetics of CF 301 vs. Placebo in Addition to Standard-of-Care Antibacterial Therapy for the Treatment of Adult Patients with Staphylococcus aureus Bloodstream Infections (Bacteremia) Including Endocarditis

The primary objectives of this study are to describe the safety and tolerability of CF-301 vs. placebo in addition to standard-of-care (SOC) antibacterial therapy for the treatment of patients with Staphylococcus aureus bloodstream infections (BSIs) including right-sided endocarditis, to estimate clinical outcome at Day 14 after CF-301/placebo administration, and to describe the pharmacokinetic (PK) parameters of CF-301.

Primary Contact Email: [email protected]

Primary Contact Phone: 781-744-2940